PMID- 37231812 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20231108 IS - 1423-0097 (Electronic) IS - 1018-2438 (Linking) VI - 184 IP - 10 DP - 2023 TI - Long-Term Omalizumab in Elderly Patients with Chronic Urticaria: Is It a Safe Therapy? PG - 1003-1009 LID - 10.1159/000530494 [doi] AB - BACKGROUND: Biologics have revolutionized the treatment of many diseases. In this regard, omalizumab (OMA), an anti-IgE monoclonal antibody, is the recommended therapeutic option for patients with chronic spontaneous urticaria (CSU) refractory to second-generation H1-antihistamines. Several studies confirm the efficacy and safety of the drug. However, the literature focusing on the elderly population is scarce, as this age group is often excluded from clinical trials. Therefore, the pharmacological treatment of CSU in elderly patients is a challenge that is increased by their comorbidities and consequent polypharmacy. OBJECTIVES: We describe the real-life safety profile of OMA in elderly patients (>/=70 years) with CSU and chronic inducible urticaria (CIndU). We aimed to provide data for daily clinical practice in this vulnerable patient group. METHOD: A retrospective review was performed of the records of patients with CSU/CIndU from May 2003 to December 2019 in the Hospital Universitario La Paz. We describe qualitative and quantitative data according to measures of central tendency. Comparisons between qualitative and quantitative data were performed with the Mann-Whitney U test and the Fisher's test for qualitative variables. A p value <0.05 was considered statistically significant. RESULTS AND CONCLUSIONS: Eighty-nine patients were included, divided into two groups (<70 vs. >/=70 years). The overall rate of adverse events (AEs) was 48%, mainly mild. No association between age and AE was found (p = 0.789). No serious AE such as anaphylaxis was detected. CSU predominated in both groups. CIndU was less prevalent in the elderly (p = 0.017). There was no association between age and the other variables. Although the frequency of neoplasms was slightly higher in the elderly with OMA, we found no difference compared to the incidence of neoplasms in the general population. Therefore, our data suggest that OMA may be a safe treatment in elderly people with CSU/CIndU for prolonged periods of treatment, although further studies with larger samples are needed to corroborate our observations. CI - (c) 2023 S. Karger AG, Basel. FAU - Narvaez-Fernandez, Emilio Jose AU - Narvaez-Fernandez EJ AD - Department of Allergy, Hospital Universitario La Paz, Madrid, Spain. FAU - Entrala, Ana AU - Entrala A AD - Department of Allergy, Hospital Universitario La Paz, Madrid, Spain. AD - Hospital La Paz Institute for Health Research, IdiPAZ, Madrid, Spain. FAU - Nin-Valencia, Ana AU - Nin-Valencia A AD - Department of Allergy, Hospital Universitario La Paz, Madrid, Spain. FAU - Mir-Ihara, Patricia AU - Mir-Ihara P AD - Department of Allergy, Hospital Universitario La Paz, Madrid, Spain. FAU - Losantos-Garcia, Itsaso AU - Losantos-Garcia I AD - Biostatistics Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain. FAU - Dominguez-Ortega, Javier AU - Dominguez-Ortega J AD - Department of Allergy, Hospital Universitario La Paz, Madrid, Spain. AD - Hospital La Paz Institute for Health Research, IdiPAZ, Madrid, Spain. AD - CIBERES, CIBER of Respiratory Diseases, Madrid, Spain. FAU - Gonzalez-Fernandez, Maria Angeles AU - Gonzalez-Fernandez MA AD - Hospital La Paz Institute for Health Research, IdiPAZ, Madrid, Spain. AD - Department of Pharmacy, Hospital Universitario La Paz, Madrid, Spain. FAU - Quirce, Santiago AU - Quirce S AD - Department of Allergy, Hospital Universitario La Paz, Madrid, Spain. AD - Hospital La Paz Institute for Health Research, IdiPAZ, Madrid, Spain. AD - CIBERES, CIBER of Respiratory Diseases, Madrid, Spain. FAU - Hernandez-Cano, Natalia AU - Hernandez-Cano N AD - Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain. FAU - Cabanas, Rosario AU - Cabanas R AD - Department of Allergy, Hospital Universitario La Paz, Madrid, Spain. AD - Hospital La Paz Institute for Health Research, IdiPAZ, Madrid, Spain. AD - Center for Biomedical Research Network on Rare Diseases, CIBERER, Madrid, Spain. AD - PIELenRed Consortium, Madrid, Spain. FAU - Caballero, Teresa AU - Caballero T AD - Department of Allergy, Hospital Universitario La Paz, Madrid, Spain. AD - Hospital La Paz Institute for Health Research, IdiPAZ, Madrid, Spain. AD - Center for Biomedical Research Network on Rare Diseases, CIBERER, Madrid, Spain. LA - eng PT - Journal Article DEP - 20230523 PL - Switzerland TA - Int Arch Allergy Immunol JT - International archives of allergy and immunology JID - 9211652 RN - 2P471X1Z11 (Omalizumab) RN - 0 (Anti-Allergic Agents) RN - 0 (Immunosuppressive Agents) SB - IM MH - Humans MH - Aged MH - Omalizumab/therapeutic use MH - *Anti-Allergic Agents/adverse effects MH - *Urticaria/drug therapy/epidemiology MH - Chronic Disease MH - *Chronic Urticaria/drug therapy MH - Immunosuppressive Agents/therapeutic use MH - Chronic Inducible Urticaria MH - *Neoplasms/drug therapy MH - Treatment Outcome OTO - NOTNLM OT - Adverse events OT - Chronic inducible urticaria OT - Chronic spontaneous urticaria OT - Elderly OT - Omalizumab OT - Safety profile OT - Treatment EDAT- 2023/05/26 06:42 MHDA- 2023/10/23 00:42 CRDT- 2023/05/26 03:45 PHST- 2022/12/07 00:00 [received] PHST- 2023/03/29 00:00 [accepted] PHST- 2023/10/23 00:42 [medline] PHST- 2023/05/26 06:42 [pubmed] PHST- 2023/05/26 03:45 [entrez] AID - 000530494 [pii] AID - 10.1159/000530494 [doi] PST - ppublish SO - Int Arch Allergy Immunol. 2023;184(10):1003-1009. doi: 10.1159/000530494. Epub 2023 May 23.